
Please try another search
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Eugene Williams | 64 | 2015 | Co-Founder & Chairman |
Neil R. Cashman | 72 | 2004 | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director |
Carsten Korth | - | 2022 | Member of Scientific Advisory Board |
Alain Dagher | - | 2022 | Member of Scientific Advisory Board |
Guy A. Rouleau | - | 2022 | Member of Scientific Advisory Board |
Cheryl Wellington | - | 2022 | Member of Scientific Advisory Board |
Neil K. Warma | 62 | 2021 | CEO, President, Compliance Officer & Director |
Michelle L. Hastings | - | - | Member of Scientific Advisory Board |
Patrick D. Kirwin | 68 | 2015 | Independent Director |
Sharon Cohen | - | 2018 | Member of Scientific Advisory Board |
William W. Wyman | 87 | 2014 | Independent Director |
Andre Strydom | - | 2019 | Member of Scientific Advisory Board |
William C. Mobley | - | 2017 | Member of Scientific Advisory Board |
Madge K. Shafmaster | 66 | 2021 | Lead Independent Director |
Joshua Mandel-Brehm | 42 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review